MapLight Therapeutics, Inc. (MPLT)

MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological disorders, headquartered in the San Francisco Bay Area. It completed its initial public offering on the Nasdaq Stock Market in 2025.

The company's research draws on circuit-level neuroscience to identify brain pathways that drive symptoms of disease. Its lead candidate, ML-007, combines a muscarinic M1 and M4 receptor agonist with a peripherally acting antagonist intended to reduce side effects outside the brain, and it is being developed for schizophrenia and for psychosis associated with Alzheimer's disease. MapLight is also advancing earlier-stage programs aimed at conditions such as autism spectrum disorder and other central nervous system disorders.